Sayfa yüklenirken bir hata oluştu.
Teknik ekibimiz bilgilendirildi, ancak sorunun devam etmesi durumunda lütfen e-posta destek widget ile bize ulaşın.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | 21,7x - 23,9x | 22,8x |
| Selected Fwd EBIT Multiple | 24,1x - 26,6x | 25,4x |
| Fair Value | ₹63,96 - ₹70,69 | ₹67,33 |
| Upside | 6,3% - 17,5% | 11,9% |
| Benchmarks | Ticker | Full Ticker |
| Hikal Limited | 524735 | BSE:524735 |
| Lupin Limited | 500257 | BSE:500257 |
| Supriya Lifescience Limited | 543434 | BSE:543434 |
| Dr. Reddy's Laboratories Limited | 500124 | BSE:500124 |
| Alembic Pharmaceuticals Limited | 533573 | BSE:533573 |
| Morepen Laboratories Limited | MOREPENLAB | NSEI:MOREPENLAB |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| 524735 | 500257 | 543434 | 500124 | 533573 | MOREPENLAB | ||
| BSE:524735 | BSE:500257 | BSE:543434 | BSE:500124 | BSE:533573 | NSEI:MOREPENLAB | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | 0.8% | 25.9% | 19.0% | 20.0% | -8.1% | 34.7% | |
| 3Y CAGR | -6.7% | 51.0% | 5.6% | 26.7% | 7.5% | 11.5% | |
| Latest Twelve Months | 33.0% | 55.9% | 50.0% | 11.3% | 10.5% | 19.6% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | 10.6% | 10.6% | 32.7% | 20.0% | 14.0% | 7.3% | |
| Prior Fiscal Year | 8.4% | 13.9% | 28.1% | 23.5% | 10.6% | 8.0% | |
| Latest Fiscal Year | 10.7% | 19.1% | 34.5% | 22.4% | 10.9% | 8.9% | |
| Latest Twelve Months | 10.7% | 19.1% | 34.5% | 22.4% | 10.9% | 8.9% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 2.77x | 3.94x | 7.39x | 3.32x | 2.92x | 1.81x | |
| EV / LTM EBITDA | 15.5x | 16.3x | 19.7x | 12.2x | 19.7x | 17.2x | |
| EV / LTM EBIT | 25.9x | 20.7x | 21.4x | 14.8x | 26.7x | 20.2x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | 14.8x | 21.4x | 26.7x | ||||
| Historical EV / LTM EBIT | 13.2x | 20.0x | 21.7x | ||||
| Selected EV / LTM EBIT | 21.7x | 22.8x | 23.9x | ||||
| (x) LTM EBIT | 1,635 | 1,635 | 1,635 | ||||
| (=) Implied Enterprise Value | 35,408 | 37,271 | 39,135 | ||||
| (-) Non-shareholder Claims * | (15) | (15) | (15) | ||||
| (=) Equity Value | 35,393 | 37,256 | 39,120 | ||||
| (/) Shares Outstanding | 548.0 | 548.0 | 548.0 | ||||
| Implied Value Range | 64.59 | 67.99 | 71.39 | ||||
| FX Rate: INR/INR | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 64.59 | 67.99 | 71.39 | 60.16 | |||
| Upside / (Downside) | 7.4% | 13.0% | 18.7% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | 524735 | 500257 | 543434 | 500124 | 533573 | MOREPENLAB | |
| Enterprise Value | 51,736 | 895,063 | 51,431 | 1,081,158 | 193,611 | 32,980 | |
| (+) Cash & Short Term Investments | 180 | 42,014 | 792 | 57,908 | 835 | 1,272 | |
| (+) Investments & Other | 95 | 873 | 632 | 15,202 | 1,272 | 72 | |
| (-) Debt | (7,647) | (54,478) | (54) | (46,766) | (12,575) | (1,051) | |
| (-) Other Liabilities | 0 | (909) | 0 | (3,778) | 14 | (307) | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 44,364 | 882,564 | 52,801 | 1,103,724 | 183,158 | 32,965 | |
| (/) Shares Outstanding | 123.3 | 456.7 | 80.5 | 832.1 | 196.6 | 548.0 | |
| Implied Stock Price | 359.80 | 1,932.50 | 656.05 | 1,326.40 | 931.80 | 60.16 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 359.80 | 1,932.50 | 656.05 | 1,326.40 | 931.80 | 60.16 | |
| Trading Currency | INR | INR | INR | INR | INR | INR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |